Details of the Drug Combination

General Information of Drug Combination (ID: DC6I55S)

Drug Combination Name
Mizoribine DZNep
Indication
Disease Entry Status REF
Lymphoid neoplasm Investigative [1]
Component Drugs Mizoribine   DMW6F0S DZNep   DM0JXBK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: Mak
Zero Interaction Potency (ZIP) Score: 5.2
Bliss Independence Score: 6.761
Loewe Additivity Score: 6.575
LHighest Single Agent (HSA) Score: 14.03

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Mizoribine
Disease Entry ICD 11 Status REF
Transplant rejection NE84 Approved [2]
Mizoribine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) TTL7C8Q IMDH1_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Mizoribine Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Expression [5]
------------------------------------------------------------------------------------
Indication(s) of DZNep
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [3]
DZNep Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adenosylhomocysteinase (AHCY) TTE2KUJ SAHH_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
DZNep Interacts with 24 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Huntingtin-interacting protein 1 (HIP1) OT7AKCFQ HIP1_HUMAN Decreases Expression [6]
Histone-lysine N-methyltransferase SUV39H1 (SUV39H1) OTDTF5BU SUV91_HUMAN Increases Expression [6]
Histone-lysine N-methyltransferase NSD2 (NSD2) OTQ6SW4R NSD2_HUMAN Increases Degradation [7]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [7]
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1) OTA675TJ GTR1_HUMAN Decreases Expression [7]
Glucose-6-phosphate 1-dehydrogenase (G6PD) OT300SMK G6PD_HUMAN Decreases Expression [7]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Increases Expression [8]
Coilin (COIL) OTP4I4DL COIL_HUMAN Increases Expression [6]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [6]
Hexokinase-2 (HK2) OTC0GCQO HXK2_HUMAN Decreases Expression [7]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Increases Expression [7]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [7]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [7]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Expression [7]
Histone-lysine N-methyltransferase EZH2 (EZH2) OTIEHTKW EZH2_HUMAN Decreases Activity [9]
Transcriptional protein SWT1 (SWT1) OTY4AFM1 SWT1_HUMAN Decreases Expression [6]
Transmembrane protein 87A (TMEM87A) OT8ATDVX TM87A_HUMAN Increases Expression [6]
Dapper homolog 3 (DACT3) OTSNQ55G DACT3_HUMAN Affects Expression [10]
Fructose-2,6-bisphosphatase TIGAR (TIGAR) OTR7NMRJ TIGAR_HUMAN Decreases Expression [7]
E3 ubiquitin-protein ligase Jade-2 (JADE2) OTVG2MYF JADE2_HUMAN Increases Expression [6]
Kelch-like protein 42 (KLHL42) OTK6WARI KLH42_HUMAN Increases Expression [6]
Two pore channel protein 1 (TPCN1) OTT4C4DI TPC1_HUMAN Decreases Expression [6]
DmX-like protein 1 (DMXL1) OTWVL31L DMXL1_HUMAN Decreases Expression [6]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Increases Response To Substance [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 24 DOT(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun. 1986 Mar 13;135(2):688-94.
4 VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37.
5 Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
6 Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
7 S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis. Chem Biol Interact. 2020 Feb 1;317:108965. doi: 10.1016/j.cbi.2020.108965. Epub 2020 Jan 28.
8 Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem Pharmacol. 2011 Feb 15;81(4):510-7. doi: 10.1016/j.bcp.2010.11.014. Epub 2010 Nov 27.
9 Upregulation of histone-lysine methyltransferases plays a causal role in hexavalent chromium-induced cancer stem cell-like property and cell transformation. Toxicol Appl Pharmacol. 2018 Mar 1;342:22-30. doi: 10.1016/j.taap.2018.01.022. Epub 2018 Jan 31.
10 DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell. 2008 Jun;13(6):529-41. doi: 10.1016/j.ccr.2008.04.019.
11 Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia. 2013 Dec;27(12):2341-50. doi: 10.1038/leu.2013.94. Epub 2013 Mar 29.